<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_NEU-China_Part_Collection skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:NEU-China/Part Collection</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><P><TITLE>Part collection - NEU-China</TITLE></P><DIV class="container"><DIV class="navbar-header"><A class="navbar-brand" href="https://2016.igem.org/Team:NEU-China"><SPAN style="font-size: 26px"><SPAN style="color: #F00;">I</SPAN><SPAN style="color: #0F0;">T</SPAN><SPAN style="color: lightblue;">S</SPAN> COLOR</SPAN></A></DIV><DIV class="collapse navbar-collapse navbar-right"><UL class="nav navbar-nav"><LI><A href="https://2016.igem.org/Team:NEU-China">Home</A></LI><LI><A href="Background">Background</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Project </A></LI><LI><A href="Description">Description</A></LI><LI><A href="Design">Design</A></LI><LI><A href="ExperimentResults">Experiment &amp; Results</A></LI><LI><A href="Proof">Proof of concept</A></LI></UL><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Lab </A></LI><LI><A href="Team">Team</A></LI><LI><A href="Attributions">Attributions</A></LI><LI><A href="LabLife">Lab Life</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Notebook </A></LI><LI><A href="Progress">Progress</A></LI><LI><A href="Protocol">Protocol</A></LI><LI><A href="Safety">Safety</A></LI><LI class="dropdown active"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Parts </A></LI><LI><A href="OurParts">Our Parts</A></LI><LI><A href="BiobricksForMedal">Biobricks for medal</A></LI><LI><A href="Basic_Part">Basic Parts</A></LI><LI><A href="Part_Collection">Part Collection</A></LI><LI class="dropdown"><A href="#" class="dropdown-toggle" data-toggle="dropdown">Human Practices </A></LI><LI><A href="Human_Practices">Human Practices</A></LI><LI><A href="Silver">Silver</A></LI><LI><A href="Gold">Gold</A></LI><LI><A href="Collaborations">Collaborations</A></LI></DIV></DIV><SECTION id="blog" class="container"><DIV class="row"><DIV class="col-md-10 col-md-offset-1"><DIV class="title-img"><H2 style="right: 5%; top: 15%;">Part collection</H2></DIV></DIV></DIV><DIV class="blog"><DIV class="row"><DIV class="col-md-10 col-md-offset-1"><DIV class="blog-item"><DIV class="row"><DIV class="col-xs-12 blog-content"><P>
                                Welcome to our Part Collection page. Here you will find all parts of our LACE toolkit
                                for gene regulation.This parts can be applied to other situations by other teams.
                            </P><TABLE class="table table-striped table-hover text-center table-bordered" style="font-size: 14px;"><TBODY><TR><TD><STRONG>Parts</STRONG></TD><TD><STRONG>Biobrick Number</STRONG></TD><TD><STRONG>Length [bp]</STRONG></TD><TD><STRONG>Designer</STRONG></TD></TR><TR><TD>tCas9-Vp64(Prokaryotic)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982006">BBa_K1982006</A></TD><TD>4368</TD><TD>NEU-China 2016</TD></TR><TR><TD>tCas9-CIBN (Prokaryotic LACE system)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982000">BBa_K1982000</A></TD><TD>4716</TD><TD>NEU-China 2016</TD></TR><TR><TD>CRY2-VP64(Prokaryotic LACE system)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982005">BBa_K1982005</A></TD><TD>2100</TD><TD>NEU-China 2016</TD></TR><TR><TD>tCas9-CIBN (Eukaryotic LACE system)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982008">BBa_K1982008</A></TD><TD>4716</TD><TD>NEU-China 2016</TD></TR><TR><TD>CRY2-VP64(Eukaryotic LACE system)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982010">BBa_K1982010</A></TD><TD>2100</TD><TD>NEU-China 2016</TD></TR><TR><TD>tCas9-Vp64(Eukaryoticc)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982011">BBa_K1982011</A></TD><TD>4368</TD><TD>NEU-China 2016</TD></TR><TR><TD>vp64</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982012">BBa_K1982012</A></TD><TD>246</TD><TD>NEU-China 2016</TD></TR><TR><TD>Prokaryotic tCAS9</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982001">BBa_K1982001</A></TD><TD>4122</TD><TD>NEU-China 2016</TD></TR><TR><TD>Prokaryotic CRY2( a blue light stimulated photoreceptor)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982002">BBa_K1982002</A></TD><TD>1854</TD><TD>NEU-China 2016</TD></TR><TR><TD>CIBN(the N-terminal fragment of CIB1)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982003">BBa_K1982003</A></TD><TD>612</TD><TD>NEU-China 2016</TD></TR><TR><TD>Eukaryotic tCAS9</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982007">BBa_K1982007</A></TD><TD>4121</TD><TD>NEU-China 2016</TD></TR><TR><TD>Eukaryotic CRY2 ( a blue light stimulated photoreceptor)</TD><TD><A href="http://parts.igem.org/Part:BBa_K1982009">BBa_K1982009</A></TD><TD>1848</TD><TD>NEU-China 2016</TD></TR></TBODY></TABLE><P class="text-center"><STRONG>Figure 1 illustrates the detailed design of the whole device</STRONG></P><H3>tCas9-CIBN (Prokaryotic LACE system)</H3><P>The NEU-China iGEM team 2016 designed a fusion protein consisting of tCas9 and CIBN for
                                sequence-specific transactivation of a desired target locus (more information). We used
                                our double truncated tCas9 (<A href="http://parts.igem.org/part:BBa_K1982001">BBa_K1982001</A>) impaired in its cleavage activity and fused
                                it to the CIBN (<A href="http://parts.igem.org/part:BBa_K1982003">BBa_K1982003</A>). An prokaryotic RBS sequence from the Community
                                collection(BBa_B0034) fused to the beginning of tCas9-CIBN. For detection of expression
                                the fusion protein was tagged with a HA-epitope coding sequence (<A href="http://parts.igem.org/part:BBa_K1150016">BBa_K1150016</A>) .
                            </P><P class="text-center"><STRONG>Figure 2: Construct design</STRONG></P><P>
                                tCas9 was fused to CIBN. The resulting fusion construct was flanked by RBS sequences
                                and tagged by a HA epitope. The pBad/araC promoter and rrnB T1 terminator were chosen
                                to control gene expression.
                            </P><H3>CRY2-VP64(Prokaryotic LACE system)</H3><P>
                                We used the full-length CRY2 (<A href="http://parts.igem.org/part:BBa_K1982002">BBa_K1982002</A>) and fused it to the transcription activator domain VP64 (<A href="http://parts.igem.org/part:BBa_K1982012">BBa_K1982012</A>). An prokaryotic RBS sequence from the Community collection(BBa_B0034) fused to the beginning of CRY2-VP64. For detection of expression the fusion protein was tagged with a FLAG-epitope coding sequence (gactacaaggacgacgacgacaaa) .
                            </P><P class="text-center"><STRONG>Figure 3: illustrates the detailed design of the this device</STRONG></P><H3>tCas9-Vp64(optogenetic control)</H3><P>
                                To address these limitations, we adapted the CRISPR/Cas9 activator system for
                                optogenetic control. We constructed tCas9-VP64 chimeric constructs gene with an
                                prokaryotic RBS sequence from the Community collection(BBa_B0034). For detection of
                                expression the fusion protein was tagged with a FLAG-epitope coding sequence
                                (gactacaaggacgacgacgacaaa)
                            </P><P class="text-center"><STRONG>Figure 4: illustrates the detailed design of the this device</STRONG></P><H2>Proof of concept</H2><P>
                                According to our design, we transfected a targeting plasmid into <I>E.coli BL21</I> to express fusion protein composed of the protein tCas9 and CIBN. Simultaneously, we transfected GFP, gRNA and CRY2-VP64 plasmid into <I>E.coli BL21</I>. Then, the promoter of GFP were continually repressed by gRNA and tCas9. When exposed to blue light, the N-terminal fragment of CIB1 (CIBN) would interact with CRY2. Subsequently, binding of the CRY2-VP64 on the upstream sequence of promoter will result in activating promoter via recruitment of the RNA polymerase II by the VP64 subunit of CRY2-VP64. Generally, the experimental procedure can be divided into four steps: 
                            </P><OL><LI>Characterization of fusion protein</LI><LI>Verification of the suppression efficiency of gRNA</LI><LI>Silencing capability validation</LI><LI>Targeting capability validation</LI></OL><H3> Characterization of fusion protein </H3><P class="text-center"><STRONG>Figure 1: Validation of protein</STRONG></P><P>CRY2-VP64:
                                Stationary cultures of <I>BL21</I> J23114 was subcultured into fresh media and growth for 4 hours. Subsequent extraction of protein from bacterial and visualization using SDS-PAGE confirms that proteins of the expected size are present in the supernatant and hence most likely successfully secreted by the engineered bacterial strains.
                            </P><P class="text-center"><STRONG>Figure 2：Western blot analysis of CRY2-VP64 protein levels.</STRONG>
                                1:Control groups transfected with empty plasmid;      2 3 4:Transfected with CRY2-VP64 plasmid (J23114 promoter) from different single colonies, ~78.5 kDa. Stationary cultures of <I>BL21 </I>was subcultured into fresh media and growth for 4 hours. 30ng of protein with total volume of 30ul (protein sample + dissociation buffer).
                            </P><P>tCas9-CIBN:                   Stationary cultures of <I>BL21</I> pBAD was subcultured into fresh media and induced for 4 hours or 16 hours using different concentrations L-arabinose. Subsequent purification of protein from the cell-free supernatant and visualization using SDS-PAGE confirms that proteins of the expected size are present in the supernatant and hence most likely successfully secreted by the engineered bacterial strains.</P><P class="text-center"><STRONG>  Figure 3：Western blot analysis of tCas9-CIBN protein levels.</STRONG>
                                     1 3 5 7 9 11:Control groups transfected with empty plasmid; 2 4 6 8 10 12: Transfected with tCas9-CIBN plasmid (pBAD promoter), ~180 kDa
. Stationary cultures of <I>BL21 </I>was subcultured into fresh media and growth for 4 hours or 16 hours using different concentrations L-arabinose. 30ng of protein with total volume of 30ul (protein sample + dissociation buffer).
                            </P><P class="text-center"><STRONG>Figure 4: Western blot analysis of tCas9-CIBN protein levels.</STRONG>
                                     1 3 5 7 9 11:Control groups transfected with empty plasmid; 2 4 6 8 10 12: Transfected with tCas9-CIBN plasmid (pBAD promoter), ~180 kDa
. Stationary cultures of <I>BL21 </I>was subcultured into fresh media and growth for 4 hours or 16 hours using different concentrations L-arabinose. 30ng of protein with total volume of 30ul (protein sample + dissociation buffer).
                            </P><H3> Verification of the suppression efficiency of gRNA</H3><P>
                                With different target loci have been tested by the usage of a GFP reporter plasmid (pCold-1) with a CSPA promotor. The target sites can be determined by directing the gRNA consisting of 20 bp length against the desired sequence of interest. F1 gRNA with target sites at different distances to the promotor regions proved successfully as potential activation sites (see Table 1 and Figure 5).
                            </P><TABLE class="table table-striped table-bordered table-responsive text-center"><TBODY><TR><TD><B>Name</B></TD><TD><B>Binding Site</B></TD><TD><B>Distance to promoter</B></TD><TD><B>Sequence</B></TD><TD><B>Position</B></TD></TR><TR><TD>F1</TD><TD>CSPA promoter</TD><TD>15</TD><TD>TGCATCACCCGCCAATGCG</TD><TD>sense sequences</TD></TR><TR><TD>F2</TD><TD>non-coding</TD><TD>68</TD><TD>GCCGCCGCAAGGAATGGTG</TD><TD>sense sequences</TD></TR><TR><TD>R1</TD><TD>CSPA promoter</TD><TD>43</TD><TD>ATTAATCATAAATATGAAA</TD><TD>antisense sequences</TD></TR><TR><TD>R2</TD><TD>non-coding</TD><TD>94</TD><TD>CATCATCCAACTCCGGCAAC</TD><TD>antisense sequences</TD></TR></TBODY></TABLE><P class="text-center"><B>Table 1: Overview of the tested gRNAs with different binding sites on the GFP pCold-1 plasmid.</B></P><P class="text-center"><STRONG>Figure 5: Position of the target loci on the GFP pCold-1 plasmid.</STRONG></P><P>To ensure the suppression efficiency of the gRNA, four gRNA sequences targeting different sites of CSPA promoter were designed and transfected into the <I>E. coli</I> strains <I>BL21</I>. Efficient suppression of CSPA promoter in strains  <I>BL21</I> was observed. GFP levels in GFP transgenic strains decrease after inserting a fragment that expresses CSPA promoter gRNA. And the sequence with the best suppression effect was selected for further study.</P><P class="text-center"><STRONG>
                                    Figure 6: Results of the GFP-influence under the CSPA promotor
                                    only using different gRNAs targeted to CSPA promoter in <I>BL21</I>.
                                </STRONG>
1-8: Transfected with different GFP-gRNA plasmid (CSPA promoter)  9:Control group transfected with GFP plasmid,~27 kDa. Excitation wavelength: 488 nm, Emission wavelength:  509nm. Stationary cultures of <I>BL21 </I>was subcultured into fresh media and growth for 8 hours (1 3 5 7 9) or 16 hours (2 4 6 8) at 30°C. 30ng of protein with total volume of 30ul (protein sample + dissociation buffer).
                            </P><H3>Silencing capability validation</H3><P>
                                We next evaluated the effect of tCas9-cibn on suppressing CSPA promoter. GFP expression levels were assayed in strains <I>BL21</I> after co-transformation with tCas9-cibn and CRY2-VP64 and gRNA in the absence of light conditions.
                            </P><P class="text-center"><STRONG>
                                    Figure 7: Silencing capability of tCas9-CIBN with gRNA  using different
                                    gRNAs targeted to CSPA promoter in <I>BL21</I>.
                                </STRONG>1-8: Transfected with different GFP-gRNA plasmid (CSPA promoter) and tCas9-CIBN plasmid (pBAD promoter)  9 10:Control groups transfected with GFP plasmid and  tCas9-CIBN plasmid (pBAD promoter), ~27 kDa. Excitation wavelength: 488 nm, Emission wavelength:  509nm. Stationary cultures of <I>BL21 </I>was subcultured into fresh media and growth for 8 hours (1 3 5 7 9) or 16 hours (2 4 6 8 10) using 15mM L-arabinose at 30°C. 30ng of protein with total volume of 30ul (protein sample + dissociation buffer).
                            </P><P>
                                Compared with control groups, green fluorescence intensity and mRNA levels were dramatically reduced in groups treated with gRNA and tCas9-CIBN. These results suggest that gRNA can specifically guide tCas9 to target upstream of CSPA promoter, thereby to inhibit CSPA promoter to reduce GFP expression levels.
                            </P><H3>Activation capability validation</H3><P>
                                Spatially controlled activation of gene expression was achieved in strains co-transfected with the LACE system, a reporter vector containing a gRNA target sequence upstream of CSPA promoter and the eGFP gene. Strains transfected with light-activated CRISPR/Cas9 effector (LACE) and incubated in the dark did not show a significant difference in eGFP levels compared to control groups transfected with empty plasmid. Strains containing the LACE system and gRNA exhibited significantly brighter eGFP fluorescence intensity when illuminated compared to when incubated in the dark. Activation of the eGFP reporter in strains transfected with the gRNA and LACE constructs, the gRNA and tCas9-VP64 expression plasmid or an empty plasmid as a negative control was quantified after 24 hours of illumination or incubation in the dark. 
                            </P><P class="text-center"><STRONG>
                                    Figure 8: Activation capability of LACE system 
                                    using gRNA-F1 plasmid and tCas9-CIBN plasmid in <I>BL21</I>.
                                </STRONG>Excitation wavelength: 488 nm, Emission wavelength:  509nm. Stationary cultures of <I>BL21 </I>was subcultured into fresh media and growth for 8 hours using 15mM L-arabinose at 30°C.
                            </P><H3>
                                Conclusion
                            </H3><P>
                                The LACE system provides a straightforward and robust optogenetic method to regulate the expression of endogenous genes using the CRISPR/tCas9 system. When co-transfected with gRNAs into <I>E.coli</I> that are stimulated with blue light, LACE produces a high level of transcriptional activation, in some cases, comparable to those observed with tCas9-VP64.
                            </P></DIV></DIV></DIV></DIV></DIV></DIV></SECTION><FOOTER id="footer" class="midnight-blue"><DIV class="container"><DIV class="row"><DIV class="col-sm-6">© 2016 NEU-China Team.
            </DIV><DIV class="col-sm-6"><UL class="pull-right"><LI><A href="https://2016.igem.org/Team:NEU-China">Home</A></LI><LI><A href="Team">Our Team</A></LI></UL></DIV></DIV></DIV></FOOTER></DIV></DIV></DIV></DIV></DIV></BODY></HTML>